What it costs and where to get it in Lincolnshire

ChondroFiller™ hip cartilage injection is available at Lincolnshire Hip's clinics in Sleaford and Grantham at £2,995 per injection. The procedure, ultrasound imaging, and consultant assessment are all delivered locally — patients in Lincolnshire and surrounding areas do not need to travel to London for any part of the injection pathway.

All consultations and injections are led by Professor Paul Y.F. Lee, who was the first clinician in the UK to offer ChondroFiller® as an outpatient injection rather than a surgical procedure. That combination — a specialist of that background, operating outside London — is uncommon for this treatment, which remains available at only a small number of centres nationally.

On cost, the Lincolnshire Hip fee of £2,995 sits at effective parity with the published single-box rate at London Cartilage Clinic, which lists £3,000 for one box inclusive of consultation, ultrasound, product, and six-week follow-up. The Lincolnshire Hip price is comparable on that basis, though patients should confirm at booking exactly which elements are bundled — for example whether a follow-up review is included — as package structures can differ between clinics.

Most focal hip defects are treated with a single box. Where a larger surface area requires two or three boxes, the total cost rises accordingly; the treating team can advise on the likely volume needed once imaging has been reviewed.

How ChondroFiller works inside the hip joint

Inside the hip joint, ChondroFiller™ works through a process called acellular matrix-induced chondrogenesis — in plain terms, the scaffold creates the right biological environment for the hip joint's own cells to migrate in and begin repair.

The product itself is a CE-marked Class III medical device: an acellular, injectable scaffold made from Type I collagen, manufactured by Meidrix Biomedicals GmbH in Germany and supplied under prescription. It contains no live cells — it is a structural matrix, not a drug or a cell therapy.

Once placed into the hip under ultrasound guidance during an outpatient appointment, the collagen self-gels within minutes, forming a stable cushion over worn cartilage surfaces. The body's own progenitor cells — drawn from the synovium and subchondral bone — migrate into this scaffold, mature into chondrocytes, and begin producing cartilage-like tissue. Over the following 12 to 24 months, the scaffold gradually biodegrades as the body's own repair tissue takes its place. The injection supports the body's own repair processes rather than substituting for them.

The outpatient nature of the procedure matters clinically. Surgical cartilage repair techniques — such as microfracture, ACI, or MACI — are a separate pathway entirely, requiring an operating theatre, a dry joint field, and general anaesthesia. ChondroFiller™ is delivered as an ultrasound-guided injection into a fluid hip joint, with no incision, no theatre admission, and no general anaesthetic required.

Which hip patients are most likely to benefit

Not every hip pain patient will be a candidate, and understanding the distinction early saves time on both sides.

ChondroFiller™ is designed for focal articular cartilage defects — areas of localised damage where the surrounding cartilage remains largely intact. Patients with early-to-moderate hip cartilage loss fall within the intended treatment window. Those with end-stage osteoarthritis, bone-on-bone disease, or Kellgren-Lawrence Grade IV degeneration are unlikely to be appropriate: the scaffold requires viable surrounding tissue to function as intended, and at that stage of deterioration a joint-preservation strategy of any kind is generally no longer the right clinical frame.

The positioning matters: ChondroFiller™ is a joint-preservation bridge, not a cure. For patients who have reached the point where some cartilage damage is confirmed but total hip replacement is not yet unavoidable, it may offer a pathway that delays — or in some cases helps avoid — that outcome. A 2023 peer-reviewed study of ultrasound-guided collagen-based injection in hip patients with KL Grade I–II disease found significant reductions in both pain (VAS) and functional limitation (WOMAC scores) at one and three months, with no adverse events recorded — providing some external support for use in that earlier disease range.

Defect size is also relevant to cost. Single-box treatment at £2,995 reflects a focal lesion; larger or multi-site defects may require additional product, with cost rising accordingly. The treating team can only advise on volume requirements after imaging has been reviewed.

A consultation with Prof Lee — including an assessment of imaging — is the necessary starting point for any suitability decision. Hip pain has many causes, and not all will qualify for this pathway.

What the clinical evidence shows for hip outcomes

A mean improvement of 33 points in the modified Harris Hip Score and a six-point VAS pain reduction represent the core hip-specific outcome picture from manufacturer-supported studies — both figures sit well above the threshold of approximately 15 points that clinicians typically regard as clinically meaningful change.

The independent 2023 peer-reviewed study cited earlier — 44 hip OA patients at Kellgren-Lawrence Grade I–II, treated with ultrasound-guided intra-articular collagen injection — adds corroboration from outside the manufacturer's own dataset, with significant improvements in VAS pain and WOMAC functional scores over NSAIDs alone at both one and three months, and no adverse events recorded in either group.

The broader safety record is worth stating clearly. The April 2025 Clinical Evaluation Report, covering more than 19,000 treated cases globally, reports a serious complication rate of approximately zero per cent and a reoperation rate of 3–8%. Published comparators include microfracture, with a reoperation rate of up to 41%, and ACI/MACI, with a complication rate of up to 17% in reported series. Those contrasts do not make ChondroFiller™ the right choice for every patient, but they represent a genuinely notable safety profile for a cartilage-targeted intervention.

The main limitation is direct: the most robust long-term data — IKDC score improvements of around 30 points at 12 months — is largely knee-derived. Hip-specific RCT evidence beyond two years has not yet been published. Patients should factor that gap into their thinking. What data does exist for the hip has moved consistently in the same direction as the wider dataset, and studies specific to the joint are continuing.

NHS funding and private medical insurance

ChondroFiller™ is not available on the NHS. It is classified as a self-funded private treatment, and no NHS commissioning pathway currently exists for it in England.

Private medical insurance (PMI) is worth exploring before ruling it out. Some UK insurers — Bupa, Aviva, and WPA are those most commonly cited in claims to date — have approved coverage on a case-by-case basis. The procedure is typically billed under CCSD code W3111 (cartilage regeneration with collagen scaffold) and, where applicable, W8500. Approval is not automatic and depends entirely on the individual policy: specific exclusions, pre-existing condition clauses, and benefit limits all vary. The essential step is to contact your insurer in writing, request pre-authorisation before any appointment is booked, and obtain confirmation in writing. Do not assume coverage based on a general description of the treatment.

For patients funding treatment themselves, the starting point is a single injection at the Grantham or Sleaford clinic — a self-contained, consultant-led outpatient appointment. Whether one treatment session is sufficient depends on defect size and imaging findings, which the consultation will clarify. The self-pay route remains straightforward to arrange, with no referral required.

What the appointment involves and next steps

For patients who have weighed the costs, mechanism, and evidence covered above, the remaining question is usually practical: what happens at the clinic, and what is worth preparing beforehand?

Bringing any existing hip imaging to the first appointment — an MRI or X-ray from a GP, a previous orthopaedic referral, or a private scan — is the most useful thing a patient can do in advance. It allows the candidacy assessment to proceed on the day rather than waiting on a separate radiology request. Where no recent hip imaging exists, this can be arranged as part of the pathway itself.

The initial consultation at either the Grantham or Sleaford site combines a full clinical history, imaging review, and physical examination in a single setting. Where the findings support ChondroFiller™, the injection is delivered as a discrete outpatient procedure under ultrasound guidance; patients arrive and leave on the same day. Approximately one to two weeks of relative rest follows before returning to normal movement, after which rehabilitation is graduated according to clinical response. A six-week follow-up review allows assessment of the early tissue response and shapes the loading and activity plan from that point.

This treatment is best suited to patients in the early-to-moderate phase of hip cartilage loss — focal damage with meaningful structural integrity remaining — whose primary goal is preserving the hip and extending the window before any surgical decision is required. For patients in that position, the pathway from first enquiry to injection is contained and consultant-led throughout.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

1. [1] Ultrasound guided injection with Collagen-based Medical Device: real-life evaluation of efficacy and safety in hip osteoarthritis. (2023). https://doi.org/10.11152/mu-4242 https://doi.org/10.11152/mu-4242